{"id":"tifcemalimab-injection","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Rash"},{"rate":"5-10%","effect":"Pruritus"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PD-1, tifcemalimab injection blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, which are expressed on tumor cells and tumor-associated immune cells. This blockade prevents the inhibition of T-cell activation and proliferation, leading to enhanced anti-tumor immune responses.","oneSentence":"Tifcemalimab injection is a monoclonal antibody that targets the PD-1 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:38:38.216Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Melanoma"}]},"trialDetails":[{"nctId":"NCT06732258","phase":"PHASE1","title":"Low-dose Radiotherapy Combined with Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC","status":"NOT_YET_RECRUITING","sponsor":"Sichuan University","startDate":"2025-01-10","conditions":"Extensive-stage Small-cell Lung Cancer","enrollment":12},{"nctId":"NCT06095583","phase":"PHASE3","title":"Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)","status":"RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2023-11-15","conditions":"Limited-stage Small Cell Lung Cancer (LS-SCLC)","enrollment":756}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Tifcemalimab injection","genericName":"Tifcemalimab injection","companyName":"Shanghai Junshi Bioscience Co., Ltd.","companyId":"shanghai-junshi-bioscience-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tifcemalimab injection is being studied as a potential treatment for Limited-stage Small Cell Lung Cancer (LS-SCLC) and Extensive-stage Small-cell Lung Cancer. The exact mechanism of action of Tifcemalimab is currently unknown.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}